ACHN-383 + ACHN-789

ACHN-383 + ACHN-789 is an **oral combination drug** investigated under the code name **C-Scape**. This combination includes two novel agents: **ACHN-383**, a beta-lactam antibiotic, and **ACHN-789**, a beta-lactamase inhibitor. The combination is designed to overcome the resistance mechanisms in extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae by inhibiting beta-lactamase enzymes and providing robust antibacterial activity. Primary clinical focus is on the treatment of infections caused by multidrug-resistant Gram-negative bacteria. The initial clinical studies—such as Phase 1 studies—have focused on safety, tolerability, pharmacokinetics, food effect, and drug-drug interactions in healthy subjects, including those with renal impairment. The developer is Achaogen.

Other names

C-Scape